Akari Therapeutics PLC (AKTX)
1.24
-0.23
(-15.65%)
USD |
NASDAQ |
Nov 21, 16:00
1.28
+0.04
(+3.23%)
After-Hours: 20:00
Akari Therapeutics Net Income (Quarterly): -2.895M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -2.895M |
| June 30, 2024 | -7.558M |
| March 31, 2024 | -5.566M |
| December 31, 2023 | -4.138M |
| September 30, 2023 | -2.871M |
| June 30, 2023 | -4.00M |
| March 31, 2023 | 1.001M |
| June 30, 2022 | -5.68M |
| March 31, 2022 | -5.176M |
| December 31, 2021 | -5.788M |
| September 30, 2021 | -1.451M |
| June 30, 2021 | -4.346M |
| March 31, 2021 | -5.838M |
| December 31, 2020 | -6.810M |
| September 30, 2020 | 0.9135M |
| June 30, 2020 | -7.440M |
| March 31, 2020 | -3.745M |
| December 31, 2019 | -7.618M |
| September 30, 2019 | -2.565M |
| June 30, 2019 | -4.117M |
| March 31, 2019 | -2.545M |
| Date | Value |
|---|---|
| December 31, 2018 | -7.545M |
| September 30, 2018 | -3.593M |
| June 30, 2018 | -8.022M |
| March 31, 2018 | -1.339M |
| December 31, 2017 | -12.12M |
| September 30, 2017 | -10.38M |
| June 30, 2017 | -0.32M |
| March 31, 2017 | -12.58M |
| December 31, 2016 | -8.286M |
| September 30, 2016 | -0.4181M |
| June 30, 2016 | -6.451M |
| March 31, 2016 | -2.985M |
| December 31, 2015 | 6.472M |
| September 30, 2015 | -48.74M |
| June 30, 2015 | -1.341M |
| March 31, 2015 | -1.697M |
| December 31, 2014 | -1.114M |
| September 30, 2014 | -0.2231M |
| June 30, 2014 | -2.229M |
| March 31, 2014 | -1.74M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-7.618M
Minimum
Dec 2019
1.001M
Maximum
Mar 2023
-4.389M
Average
-4.761M
Median
Net Income (Quarterly) Benchmarks
| DBV Technologies SA | -30.44M |
| Cellectis SA | -23.06M |
| Adaptimmune Therapeutics PLC | -17.62M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -8.826M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.852M |
| EPS Diluted (Quarterly) | -0.2374 |
| Enterprise Value | 24.35M |
| Earnings Yield | -221.9% |